Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan.
COVID-19
SARS-CoV-2
SARS-CoV-2 IgG antibodies
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
01 Jun 2022
01 Jun 2022
Historique:
pubmed:
29
3
2022
medline:
7
6
2022
entrez:
28
3
2022
Statut:
ppublish
Résumé
Objective Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally. Although the relationship between anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies and COVID-19 severity has been reported, information is lacking regarding the seropositivity of patients with particular types of diseases, including hematological diseases. Methods In this single-center, retrospective study, we compared SARS-CoV-2 IgG positivity between patients with hematological diseases and those with non-hematological diseases. Results In total, 77 adult COVID-19 patients were enrolled. Of these, 30 had hematological disorders, and 47 had non-hematological disorders. The IgG antibody against the receptor-binding domain of the spike protein was detected less frequently in patients with hematological diseases (60.0%) than in those with non-hematological diseases (91.5%; p=0.029). Rituximab use was significantly associated with seronegativity (p=0.010). Conclusion Patients with hematological diseases are less likely to develop anti-SARS-CoV-2 antibodies than those with non-hematological diseases, which may explain the poor outcomes of COVID-19 patients in this high-risk group.
Identifiants
pubmed: 35342138
doi: 10.2169/internalmedicine.9209-21
pmc: PMC9259303
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1681-1686Références
Leukemia. 2020 Nov;34(11):3047-3049
pubmed: 32855439
Clin Infect Dis. 2021 Jan 27;72(2):301-308
pubmed: 33501951
J Clin Immunol. 2013 Feb;33(2):388-96
pubmed: 23064976
Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):774-776
pubmed: 32933879
Blood. 2020 Nov 12;136(20):2290-2295
pubmed: 32959052
Infect Control Hosp Epidemiol. 2021 Oct;42(10):1286-1288
pubmed: 33023685
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
Nat Rev Immunol. 2020 Oct;20(10):615-632
pubmed: 32887954
Br J Haematol. 2021 Nov;195(3):371-377
pubmed: 34272724
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Nat Cancer. 2021 Apr;2(4):392-399
pubmed: 34661163
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
Nat Commun. 2020 Nov 27;11(1):6044
pubmed: 33247152
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Science. 2020 Aug 28;369(6507):1119-1123
pubmed: 32661058
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
J Med Virol. 2020 Oct;92(10):1755-1756
pubmed: 32270882
Br J Haematol. 2020 Jul;190(2):185-188
pubmed: 32557623
Ann Oncol. 2020 Aug;31(8):1087-1088
pubmed: 32360743
Rinsho Ketsueki. 2020;61(8):857-864
pubmed: 32908046
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
EClinicalMedicine. 2021 Feb;32:100734
pubmed: 33589882
J Hematol Oncol. 2020 Jul 14;13(1):94
pubmed: 32664919
Blood Adv. 2020 Oct 13;4(19):4864-4868
pubmed: 33031540
Blood. 2013 Sep 12;122(11):1946-53
pubmed: 23851398
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Clin Infect Dis. 2020 Nov 5;71(8):1930-1934
pubmed: 32306047
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
J Infect Dis. 2020 Jun 29;222(2):183-188
pubmed: 32358956
Semin Hematol. 2010 Apr;47(2):187-98
pubmed: 20350666
Int J Cancer. 2020 Dec 1;147(11):3267-3269
pubmed: 32525566
Ann Oncol. 2021 Jan;32(1):113-119
pubmed: 33098994
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551